NTLA | Intellia Therapeutics, Inc.

Why Intellia May Have Changed Medicine Forever
Genomics and gene editing is a sector that is truly in its infancy, but as we have seen this past week, that’s not stopping investors from buying up companies in the sector at high valuations.
By Mike Sakuraba | 3 weeks ago

Is Intellia a Buy after its early success this year?
We all know about the red-hot sectors like electric vehicles, SPAC IPOs, and cloud based software, but the real investors know that the next industry to truly take off is in biotech, specifically in genomics.
By Mike Sakuraba | 6 months ago